Background: Breast cancer is the most common cancer in women worldwide, second most common malignancy in Egypt. Methods: 60 early-stage breast cancer patients who underwent breast-conserving surgery were clusterized into 2 groups: Arm A hypofractionation with concomitant boost and Arm B conventional fractionation, each compromising 30 early stage breast cancer patients. Assessment of cosmetic outcome after breast irradiation was recorded in both groups in 4 intervals to correlate cosmesis in relation to different irradiation schedules and boost dosage and timing. The study was conducted from April 2016 till December 2018, 32 months were obtained to assure that all patients completed their irradiation schedule and 12 months follow-up period. Results: Lowest cosmetic outcome was recorded immediately after completion of breast irradiation with excellent/good in 66.7% and 73.3% of patients and fair/poor in 33.3% and 26.7% in Arm A and B, respectively. Improvement in cosmesis after 12 months of breast irradiation reaching excellent/good in 83.4% and fair/poor in 16.7% in both Arm A and B. Conclusion: An abbreviated 4-week hypofractionated schedule with a concomitant boost is as effective as conventional irradiation with comparable cosmesis and may be a reasonable alternative following breast conserving surgery.
INTRODUCTION
reast cancer is the most common cancer in women worldwide with an incidence of 1.67 million new cases and 521,900 deaths and the second most common cancer overall (1, 2) . The five-year relative survival rate for women diagnosed with localized, node-negative breast cancer is 98.5 percent. In Egypt, breast cancer ranked second after liver cancer, which with bladder cancer contributed to approximately 46% of all cancers. Among females, the proportion of breast cancer was highest in upper Egypt (38.7%), less in lower Egypt and lowest in middle Egypt (33.2%, 26.8% respectively). Incidence of breast cancer in Egypt per 100,000 population was 35.8/100,000 in females and 0.6/100,000 in males (3) . Adjuvant whole-breast radiation (WBRT) after breast conserving surgery (BCS) is a standard option for early breast cancer (EBC), as it decreases local recurrence, with
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June 2019 Volume 25 Issue 3 www.zumj.journals.ekb.eg 465 a benefit on overall survival (4, 5) . Adding a boost dose to the tumour bed (TB) further raises local control (LC) (6, 7) . Traditionally, WBRT has been delivered over 5 weeks with conventional fractionation (1.8-2 Gy daily) to a total dose of 50 Gy, followed by a sequential [10] [11] [12] [13] [14] [15] [16] Gy boost dose to the tumour bed for an overall treatment time (OTT) of 6-7 weeks (5). However, mainly due to resource constraints, altered schedules employing larger dose per fraction delivered in fewer treatment sessions over a shorter overall treatment time were introduced (8, 9) . Hypofractionation represents a safe and effective approach, as a convenient option both for patients and health care providers' convenience as it allows for reduction in hospital visits and increase in patients turnover, globally decreasing treatment costs (35) (36) . Radiobiologically, since in breast cancer the α/β ratio values for tumour and surrounding normal tissue substantially merge, a larger fraction size, with a concomitant slender total dose decrease, is likely to give a comparable tumour control probability with the same rate of expected late effects, compared to conventional fractionation (10, 11) . Treatment acceleration (through hypofractionation), with OTT reduction below 6-7 weeks, might ameliorate cure rates narrowing the time for proliferation and repopulation (12, 13) . The concomitant delivery of the TB boost along with WBRT further reduces OTT, with an eventual ulterior gain (7, 14) . The results of retrospective studies of hypofractionated radiotherapy in early breast cancer suggest satisfactory outcomes in terms of tumour control and late adverse effects (15) (16) (17) , this applies when modest increases in fraction size are combined with consequent and appropriate downward adjustments of the total dose (18) (19) (20) (21) .
More consistently, the prospective setting of randomized controlled trials also seems to adjunct confirmatory evidence upon the equivalence between hypofractionation and conventional fractionation as an adjuvant approach for early breast cancer (22) (23) (24) (25) (26) (21) . Collectively, all of the studies showed a high excellent/good cosmetic outcome after hypofractionation.
PATIENTS AND METHODS The radiation treatment was delivered within 15 days after breast conserving surgery. Patients were clusterized into 2 groups, each compromising 30 patients. The first group (Arm A) received a cumulative nominal dose of 50 Gy with a dose of 45 Gy prescribed to the ICRU reference point dose to whole breast (WB-PTV) using 3D conformal field arrangement of 2 wedged opposing 6 MV tangential fields (2.25 Gy upto 45 Gy/20 fractions) and an additional daily concomitant direct 6 MV field boost to the surgical cavity (CB-PTV) (0.25 Gy upto 5 Gy/20 fractions) with a total treatment time of 4 weeks, whilst, the second group (Arm B) received a cumulative nominal dose of 55 Gy with a dose of 45 Gy to the whole breast (1.8 Gy upto 45 Gy/25 fractions) followed by an additional daily boost to the surgical cavity (2 Gy upto 10 Gy/5 fractions) with a total treatment time of 6 weeks. For setup, patients were positioned on a wingboard with both arms raised above the head and radiopaque markers along breast borders. Subsequently, the 5-mm slice-thick axial CT images were acquired from the lower mandible aspect to lung bases; an isocenter was found in virtual simulation. The whole-breast clinical target volume (WB-CTV) encompassed breast palpable tissue, with a superior-inferior border within the extent of the radiopaque catheters. A uniform limit of 5 mm separated the WB-CTV from the skin surface and the thoracic wall. The whole-breast planning target volume (WB-PTV) was generated by adding a 5-mm isotropic margin around the WB-CTV. The definition of the tumour bed was driven by radio-opaque clips placed during surgery. The concomitant boost clinical target volume (CB-CTV) was generated by adding a 5-mm isotropic margin around the tumour bed, the consequent planning target volume (CB-PTV) required a further margin of 5 mm around the CB-CTV. In both arm A and arm B the same isocenter was used for both tangents and boost field. This was also used as the normalization point. The acceptable levels of coverage for both WB-PTV and CB-PTV were as follows: 95 % of PTV is required to receive a minimum of 95 % dose and 99 % of PTV to receive a minimum of 90 % dose. For setup verification purposes, tangential fields' portal images were compared to digitally reconstructed radiographs (DRRs). Cosmetic assessment was recorded after completion of radiotherapy and after 3, 6 and 12 months, using the Harvard criteria (4-point Likert scale) (27-28-29). Cosmosis was defined by: excellent, good, fair or poor, differentiating both the treated breast and the unaffected breast. (30) . Median boost volume irradiated in Arm A was 35cc (10-103), whereas, slightly less in Arm B 20cc (10-93). Charfare et al noted that the percentage of breast volume excised can influence the cosmetic result, removal of a larger percentage volume gives a poor cosmetic result and a smaller percentage volume an excellent/good result, 45-65% of patients with <10% estimated breast volume excised had good to excellent cosmetic result compared with 35-50% good to excellent result if >10% breast volume was excised (33) . CONCLUSION An abbreviated 4-week hypofractionated schedule with a concomitant boost is as effective as conventional irradiation with comparable cosmesis and may be a reasonable alternative following breast conserving surgery.
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